(12) United States Patent
`Manku et al.
`
`(10) Patent No.:
`(45) Date of Patent:
`
`US 8,642,077 B2
`*Feb. 4, 2014
`
`USOO8642077B2
`
`(54) STABLE PHARMACEUTICAL
`COMPOSITION AND METHODS OF USING
`SAME
`
`(71) Applicant: Amarin Pharmaceuticals Ireland
`Limited, Dublin (IE)
`
`(72) Inventors: Mehar Manku, Birmingham (GB); Ian
`Osterloh, Kent (GB); Pierre Wicker,
`Mystic, CT (US); Rene Braeckman,
`Richboro, PA (US); Paresh Soni,
`Mystic, CT (US)
`
`(51) Int. Cl.
`469/48
`A63L/232
`A619/00
`A6IP 9/00
`A6IP 9/10
`(52) U.S. Cl.
`USPC ........... 424/451; 424/400; 424/456; 514/549;
`514/560
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`(58) Field of Classification Search
`USPC ................... 424/400, 451, 456; 514/549, 560
`See application file for complete search history.
`
`(73) Assignee: Amarin Pharmaceuticals Ireland
`Limited, Dublin (IE)
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`(*) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`This patent is Subject to a terminal dis
`claimer.
`
`(21) Appl. No.: 13/768,906
`(22) Filed:
`Feb. 15, 2013
`(65)
`Prior Publication Data
`US 2013/O165513 A1
`Jun. 27, 2013
`
`Related U.S. Application Data
`(63) Continuation of application No. 13,685,291, filed on
`Nov. 26, 2012, which is a continuation of application
`No. 13/614,111, filed on Sep. 13, 2012, now Pat. No.
`8.454,994, which is a continuation of application No.
`13/458,496, filed on Apr. 27, 2012, now Pat. No.
`8.445,003, which is a continuation of application No
`12,769 885 filed on Apr. 29, 2010, now Pat No.
`8.298,554.
`•
`1 - 9
`s
`y x^ -
`s1 - Y-sa-Ya-
`•
`(60) Provisional application No. 61/173,763, filed on Apr.
`29, 2009.
`
`4,377,526 A
`4,526,902 A
`
`3/1983 Fujita et al.
`7, 1985 Rubin
`(Continued)
`
`FOREIGN PATENT DOCUMENTS
`
`CA
`CA
`
`5/2007
`2628.305
`12/2007
`2653787
`(Continued)
`OTHER PUBLICATIONS
`Anderson (The American Journal of Cardiology, 2008; 101:23F
`33F).*
`
`(Continued)
`Primary Examiner — Aradhana Sasan
`(74) Attorney, Agent, or Firm — Perkins Coie LLP
`(57)
`ABSTRACT
`The present invention relates to, inter alia, pharmaceutical
`compositions comprising a polyunsaturated fatty acid and to
`methods of using the same to treat or prevent cardiovascular
`related diseases.
`
`19 Claims, 2 Drawing Sheets
`
`
`
`E
`s
`S.
`d
`f
`
`E
`
`A.
`
`8 12 13 20 24 28 32 3 40 A4 48
`Time (hours)
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1001, p. 1 of 29
`
`

`

`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,920,098
`4,935,243
`5,013,443
`5,116,871
`5,178,873
`5, 198,468
`5,215,630
`5,252.333
`5,457,130
`5,502.077
`5,567,730
`5,589,508
`5,603,959
`5,618,558
`5,656,667
`5,698,594
`5,760,081
`5,776,978
`5,837,731
`5,840,944
`5,888,541
`6,069,168
`6,193.999
`6,326,031
`6,331,568
`6,368,621
`6,384,077
`6.479,544
`6,531,150
`6,555,700
`6,689,812
`7,119,118
`7,498.359
`8,188,146
`8,293,727
`8,293,728
`8,298,554
`8,314,086
`8,318,715
`8.324, 195
`8,357,677
`8,367,652
`8,377,920
`2002fOO16312
`2002.0035125
`2002/005.5529
`2002fOO55539
`2002fOO77361
`2002/0183389
`2002.0193439
`2002fO1981.77
`2003/010.0610
`2003/0104.048
`2003. O166614
`2004/OO77723
`2004O162348
`2005/O187292
`2006.0034.815
`2006/01341.78
`2006, O1356.10
`2006, O141022
`2006, O142390
`2006/0211762
`2006/0211763
`2006/0217356
`2006/0252833
`2007/O104779
`2007/0105954
`2007, 0141138
`2007/01675.20
`2007/O191467
`2008.0020018
`2008.0089876
`2008.0113046
`2008/O125490
`
`4, 1990
`6, 1990
`5, 1991
`5, 1992
`1, 1993
`3, 1993
`6, 1993
`10, 1993
`10, 1995
`3, 1996
`10, 1996
`12, 1996
`2, 1997
`4, 1997
`8, 1997
`12, 1997
`6, 1998
`7, 1998
`11, 1998
`11, 1998
`3, 1999
`5, 2000
`2, 2001
`12, 2001
`12, 2001
`4, 2002
`5, 2002
`11, 2002
`3, 2003
`4, 2003
`2, 2004
`10, 2006
`3, 2009
`5, 2012
`10, 2012
`10, 2012
`10, 2012
`11, 2012
`11, 2012
`12, 2012
`1, 2013
`2, 2013
`2, 2013
`2, 2002
`3, 2002
`5, 2002
`5, 2002
`6, 2002
`12, 2002
`12, 2002
`12, 2002
`5/2003
`6, 2003
`9, 2003
`4, 2004
`8, 2004
`8, 2005
`2, 2006
`6, 2006
`6, 2006
`6, 2006
`6, 2006
`9, 2006
`9, 2006
`9, 2006
`11, 2006
`5/2007
`5/2007
`6, 2007
`7/2007
`8, 2007
`1, 2008
`4, 2008
`5/2008
`5/2008
`
`Cotter et al.
`Borkan et al.
`Higashidate et al.
`Horrobin et al.
`Horrobin et al.
`Horrobin
`Hata et al.
`Horrobin
`Tisdale et al.
`Breivik et al.
`Miyashita et al.
`Schlotzer et al.
`Horrobin et al.
`Horrobin et al.
`Breivik et al.
`Breivik et al.
`Leaf et al.
`Bruzzese
`Vaddadi
`Furihata et al.
`Horrobin et al.
`Horrobin et al.
`Gennadios
`Hsia et al.
`Horrobin
`Engel et al.
`Peet
`Horrobin
`Sunohara et al.
`Horrobin et al.
`Peet
`Peet
`Yokoyama et al.
`Peet et al.
`Manku et al.
`Manku et al.
`Manku
`Manku et al.
`Manku et al.
`Manku et al.
`Manku et al.
`Manku et al.
`Manku et al.
`Seed et al.
`Shear
`Bisgaier et al.
`Bockow et al.
`Peet
`Peet
`Peet
`Horrobin et al.
`Shibuya et al.
`Patel et al.
`Harrison, Jr.
`Granata
`Peet
`Aoki et al.
`Guzman et al.
`Doisaki et al.
`Bortz et al.
`Kawamura et al.
`Manku et al.
`Rongen
`Fawzy et al.
`Wright et al.
`Peet
`Rongen et al.
`Puri
`Feuerstein et al.
`Bruzzese
`Rongen et al.
`Moodley et al.
`CavaZZa
`Gardette
`Svensson et al.
`
`US 8,642,077 B2
`Page 2
`
`8, 2008 Peet et al.
`2008/0200547 A1
`2008/0306154 A1 12/2008 Svensson et al.
`2008/0319077 A1 12/2008 Suzuki et al.
`2009 OO12167 A1
`1/2009 Rongen et al.
`2009,0182049 A1
`7/2009 Opheim
`2009/02276O2 A1
`9, 2009 Griffin et al.
`20090304784 A1 12/2009 Mane et al.
`2010, 0021555 A1
`1/2010 Geiringer et al.
`2010, 0119598 A1
`5, 2010 Yoshinarietal.
`2010/031 1834 A1 12/2010 Manku et al.
`2011/OO34555 A1
`2/2011 Osterloh et al.
`2011/0288.171 A1 11/2011 Manku et al.
`2012/010O208 A1
`4/2012 Manku
`
`FOREIGN PATENT DOCUMENTS
`
`CA
`CA
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`FR
`GB
`GB
`GB
`GB
`JP
`KR
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`2675836
`272.4983
`O 302 482
`O 460917
`O 606012
`O 610506
`1296 670
`1157 692
`1743 644
`2022.495
`2635 263
`2148 713
`2221843
`2229363
`990 1809.5
`O4 182426
`10-2006-0.109988
`90.04391
`92.21335
`94.28891
`97.397.59
`98.16216
`99.29316
`00/44361
`OO/51573
`O1/15552
`O2/O2105
`O2/O58793
`O2/O89787
`02/0964.08
`O3,068216
`2004/050913
`2004/078166
`2004/082402
`2007/O16256
`2007/017240
`2007 O73176
`2007/075841
`2007/1288O1
`2007 142118
`2008.004900
`2008/045465
`2008/106787
`2009 OO4999
`
`T 2008
`11, 2009
`2, 1989
`12/1991
`T 1994
`8, 1994
`4/2003
`10/2005
`1, 2007
`2, 2011
`2, 2009
`6, 1985
`2, 1990
`9, 1990
`1, 1999
`6, 1992
`10, 2006
`5, 1990
`12/1992
`12/1994
`10, 1997
`4f1998
`6, 1999
`8, 2000
`8, 2000
`3, 2001
`1, 2002
`8, 2002
`11, 2002
`12/2002
`8, 2003
`6, 2004
`9, 2004
`9, 2004
`2, 2007
`2, 2007
`6, 2007
`7/2007
`11, 2007
`12/2007
`1, 2008
`4/2008
`9, 2008
`1, 2009
`
`OTHER PUBLICATIONS
`
`Aarsland, et al., “On the Effect of Peroximsomal B-Oxidation and
`Carnitine Palmitoyltransferase Activity by Eicosapentaenoic Aid in
`Live and Heart of Rats.” Lipids, 25:546-548, (1990).
`Aas, V., et al., “Eicosapentaenoic acid (20:5 n-3) increases fatty acid
`and glucose uptake in cultured human skeletal muscle cells.' Journal
`of Lipid Research, 47:366-374 (2006).
`Abbey, M., et al., “Effect of fish oil on lipoproteins,
`lecithin:cholesterol acyltransferase, and lipidtransfer protein activity
`in humans' Arterioscler. Thromb. Vasc. Biol. 10:85-94 (1990).
`Ackman et al., The “Basic' Fatty Acid Composition of Atlantic Fish
`Oils: Potential Similarties Useful for Enrichment of Polyunsaturated
`Fatty Acids by Urea Complexation, JAOCS, vol. 65. 1: 136-138 (Jan.
`1988).
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1001, p. 2 of 29
`
`

`

`US 8,642,077 B2
`Page 3
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Adan, Y, et al., “Effects of docosahexaenoic and eicosapentaenoic
`acid on lipid metabolism, eicosanoid production, platelet aggregation
`and atherosclerosis.” Biosci. Biotechnol. Biochem. 63(1), 111-119
`(1999).
`Adan, Y., et al., “Concentration of serum lipids and aorticlesion size
`in female and male apo E-deficient mice fed docosahexaenoic acid.”
`Biosci. Biotechnol. Biochem. 63(2):309-313 (1999).
`Agren, J.J., et al., “Fatty acid composition of erythrocyte, platelet,
`and serum lipids in strict vegans.” Lipids 30:365-369 (1995).
`Agren, J.J., et al., “Fish diet, fish oil and docosahexaenoic acid rich oil
`lower fasting and postprandial plasma lipid levels.” Eur J. Clin Nutr.
`1996:50:765-771.
`Ait-Said, et al., “Inhibition by eicosapentaenoic acid of IL-1B-in
`duced PGHS-2 expression inhuman microvascular endothelial cells:
`involvement of lipoxygenase-derived metabolites and p38 MAPK
`pathway.” Biohimicia et Biophysica Acta, 1631:66-85 (2003).
`Alderman, J.D., et al., (1989) Effect of a modified, well-tolerated
`niacin regimen on serum total cholesterol, high density lipoprotein
`cholesterol and the cholesterol to high density lipoprotein ratio. Am.
`J. Cardio, 64: 725-729.A.
`Alessandri, J-M., et al., “Estradiol favors the formation of
`eicosapentaenoic acid (20:5n-3) and n-3 docosapentaenoic acid
`(22:5n-3) from alpha-linolenic acid (18:3n-3) in SH-SY5Y
`neuroblastoma cells.” Lipids 43:19-28 (2008).
`Allred, C., et al., “PPARY 1 as a molecular target of eicosapentaenoic
`acid in human colon cancer (HT-29) cells.” J. Nutr. 138:250-256
`(2008).
`Amarin Corporation Announces First Patients Enrolled in Two Phase
`3 Clinical Trials Assessing AMR101 for the Treatment of Cardiovas
`cular Disease online, Amarin Corporation, Jan. 11, 2010 retrieved
`Apr. 27, 2011). Retrieved from the Internet: <http://inestor.
`amarincorp.com/releasedetail.cfm?ReleaseID=504380>.
`Ando, M., et al., “Eicosapentanoic acid reduces plasma levels of
`remnant lipoproteins and prevents in vivo peroxidation of LDL in
`dialysis patients.” J. Am. Soc. Nephrol., 10:2177-2184 (1999).
`Ando. Y., et al., “Positional distribution of highly unsaturated fatty
`acids in triacyl-sn-glycerols of Artemia Nauplii enriched with
`docosahexaenoic acid ethyl ester.” Lipids 36:733-740 (2001).
`Andrade, S.E., et al., (1995) Discontinuation of antihyperlipidaemic
`drugs do rates reported in clinical trials reflect rates in primary care
`settings? New Eng. J. Med. 332: 1125-1131.
`Angerer, P. et al., “n-3 Polyunsaturated Fatty Acids and the Cardio
`vascular System”. Current Opinion in Lipidology, 11(1):57-63,
`2000.
`Anil, E., “The Impact of EPA and DHA on Blood Lipids and
`Lipoprotein Metabolism: Influence of ApoE Genotye'. Proceedings
`of the Nutrition Society, 66:60-68, 2007.
`Appelton, K.M., et al., “Effects of n-3 long-chain polyunsaturated
`fatty acidson depressed mood: systematic review of published trials.”
`Am. J. Clin. Nutr. 84(6): 1308-1316 (Dec. 2006).
`Arrol, S. et al., “The effects of fatty acids on apolipoprotein B secre
`tion by human hepatoma cells (HEP G2).” Atherosclerosis 150
`(2000) 255-264.
`Arshad, A., et al., “Sudden cardiac death and the role of medical
`therapy.” Progress in Cardiovascular Diseases, vol. 50, No. 6, 420
`438, (2008).
`Arterburn, L., et al., “Distribution, interconversion, and dose
`response of n-3 fatty acids in humans.” Am J Clin Nutr., 83:1467S
`76S (2006).
`Asano, M., et al., “Eicosapentaenoic acid inhibits vasopressin-acti
`vated Ca2q influx and cell proliferation in rat aortic Smooth muscle
`cell lines.” European Journal of Pharmacology 379: 199-209 (1999).
`Asano, M., et al., “Inhibitory effects of co-3 polyunsaturated fatty
`acids on receptor-mediated non-selective cation currents in rat A7 r5
`vascular smooth muscle cells.” British Journal of Pharmacology
`120:1367-1375, (1997).
`ATP III guidelines, NIH publication No. 01-3305 (2001).
`
`Ayton, et al., “A pilot open case series of Ethyl-EPA Supplementation
`in the treatment of anorexia nervosa. Prostaglandins, Leukotrienes
`and Essential Fatty Acids 71 (2004) pp. 205-209.
`Ayton, et al., “Rapid improvement of severe anorexia nervosa during
`treatment with ethyl-eicosapentaenoate and micronutrients.” Euro
`pean Psychiatry 19 (2004) pp. 317-319.
`Baigent, C., et al., “Efficacy and safety of cholesterol-lowering treat
`ment: prospective meta-analysis of data from 90,056 participants in
`14 randomised trials of statins.” Lancet. 2005:366:1267-1278.
`Balk, E.M., et al., “Effects of omega-3 fatty acids on serum markers
`of cardiovascular disease risk: a systematic review. Atherosclerosis.”
`2006; 189:19-30.
`Ballantyne et al., Influence of low-high density lipoprotein choles
`terol and elevated triglyceride on coronary heart disease events and
`response to simvastatin therapy in 4S, Circulation 2001, 104:3046
`3051.
`Bang HO, Dyerberg J. "Plasma lipids and Lipoproteins in
`Greenlandic west coast Eskimos' Acta MedScand 1972; 192:85-94.
`Banga, A., et al., “Adiponectin translation is increased by the PPARY
`agonists pioglitaZone and (D-3 fatty acids.” Am J Physiol Endocrinol
`Metab 296:480-489 (2009).
`Bansal S. Buring JE, Rifai N. Mora S. Sacks FM, Ridker PM, “Fast
`ing Compared With Nonfasting Triglycerides and Risk of Cardiovas
`cular Events in Women. JAMA 2007; 298:309-316.
`Basu, A., et al., “Dietary Factors That Promote or Retard Inflamma
`tion.” Arterioscler. Thromb. Vasc. Biol. 26:995-1001 (2006).
`Bays HE et al. “Prescription omega-3 fatty acids and their lipid
`effects: physiologic mechanisms of action and clinical implications.”
`Expert Rev Cardiovasc Ther 2008; 6:391-409.
`Bays, H., Clinical Overview of Omacor: A Concentrated Formulation
`of Omega-3 Polyunsaturated Fatty Acids, Am J cardiol
`2006:98suppl;71 i-76i.
`Bays, H., “Rationale for Prescription Omega-3-Acid Ethyl Ester
`Therapy for Hypertriglyceridemia: A Primer for Clinicians.” Drugs
`of Today 2008.44(3): 205-246.
`Bays, H.E., et al., "Long-term up to 24-month efficacy and safety of
`concomitant prescription omega-3-acid ethyl esters and simvastatin
`in hypertriglyceridemic patients.” Curr Med Res Opin. 2010:26:907
`915.
`Bays, H.E., Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy
`in Patients With Very High Triglyceride Levels (from the Multi
`center, plAcebo-controlled, Randomized, double-blINd, 12-week
`study with an open-label Extension MARINE Trial) Am J Cardiol
`2011; 108:682-690.
`Beal, M.F., Annals of Neurology, vol. 38, No.3, "Aging, Energy, and
`Oxidative Stress in . . .
`. pp. 357-366, Sep. 1995.
`Belmaker, et al., “Addition of Omega-3 Fatty Acid to Maintenance
`Medication Treatment for Recurrent Unipolar Depressive Disorder.”
`Am J Psychiatry 2002: 159:477-479.
`Belmaker, et al., “Omega-3 Eicosapentaenoic Acid in Bipolar
`Depression: Report of a Small Open-Label Study.” JClin Psychiatry
`2005 66:726-729.
`Bénistant, C., et al., “Docosapentaenoic acid (22:5, n-3): metabolism
`and effect on prostacyclin production in endothelial cells.”
`Prostaglandins, Leukotrienes and Essential Fatty Acids, 55(4):287
`292, (1996).
`Berge, R.K., et al., “In contrast with docosahexaenoic acid,
`eicosapentaenoic acid and hypolipidaemic derivatives decrease
`hepatic synthesis and Secretion of triacylglycerol by decreased
`diacylglycerol acyltransferase activity and stimulation of fatty acid
`oxidation.” Biochem J. 1999; 343(Pt 1):191-197.
`Betteridge, D.J., “Diabetic dyslipidaemia: past, present and future.”
`Practical Diabetes Int, 21(2): 78-85. (2004).
`Black, K.L., et al., “Effect of intravenous eicosapentaenoic acid on
`cerebral blood flow, edema, and brain prostaglandins in ischemic
`gerbils'. Prostaglandins (1984), 28(4), pp. 545-546.
`Blankenhorn, D.H., et al., (1987) Beneficial effects of combined
`collestipol-naicin therapy on coronary atheroscherosis and coronary
`venous bypass grafts. JAMA257: 3233-3240.
`Block, R. C., et al., "EPA and DHA in blood cell membranes from
`acute coronary syndrome patients and controls.” Atherosclerosis,
`197(2):821-828 (2007).
`Blumenthal (Advanced Studies in Medicine (2002) 2: 148-157).
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1001, p. 3 of 29
`
`

`

`US 8,642,077 B2
`Page 4
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Bonaa, KH et al., Docosahexaenoic and Eicosapentaenoic acids in
`plasma phospholipids are divergently associated with high density
`lipoprotein in humans, Arterioscler. Thromb. Vasc. Biol.
`1992:12:675-681.
`Bousserouel, S., et al., “Different effects of n-6 and n-3 polyunsatu
`rated fatty acids on the activation of rat Smooth muscle cells by
`interleukin-1 f.” J. Lipid Res. 44:601-611 (2003).
`Bousserouel, S., et al., “Modulation of cyclin D1 and early growth
`response factor-1 gene expression in interleukin-13-treated rat
`Smooth muscle cells by n-6 and n-3 polyunsaturated fatty acids.” Eur.
`J. Biochem. 271:4462-4473 (2004).
`Brady, L., et al., Increased n-6 polyunsaturated fatty acids do not
`attenuate the effects of long-chain n-3 polyunsaturated fatty acids on
`insulin sensitivity or triacylglycerol reduction in Indian Asians. Am J
`Clin Nutr 79.983-91 (2004).
`Breslow, J., “n-3 Fatty acids and cardiovascular disease.” Am J Clin
`Nutr., 83: 1477S-82S (2006).
`Brossard, N., et al., “Retroconversion and metabolism of
`13CI22:6n-3 in humans and rats after intake of a single dose of
`13CI22:6n-3-3-triacyylglycerols.” Am. J. Clin. Nutr. 64:577-86
`(1996).
`Brouwer, I.A., et al., “Effect of fish oil on ventricular
`tachyarrhythmia and death in patients with implantable cardioverter
`defibrillators.” JAMA. 295(22):2613-2619 (2006).
`Brown et al., Simvastatin and Niacin, Antioxidant Vitamins, or the
`Combination for the Prevention of Coronary Disease, N Engl J Med,
`vol. 345, No. 22, Nov. 29, 2001.
`Brown, A.J., et al., “Administration of n-3 Fatty Acids in the Diets of
`Rats or Directly to Hepatocyte Cultures Results in Different Effects
`on Hepatocellular ApoB Metabolism and Secretion.” Arterioscler.
`Thromb. Vasc. Biol. 19:106-114 (1999).
`Brown, A. J., et al., “Persistent changes in the fatty acid composition
`of erythrocyte membranes after moderate intake of n-3 polyunsatu
`rated fatty acids: study design and implications.” Am.J. Clin. Nutri.
`54:668-73(1991).
`Brown, G., et al., (1990) Regression of coronary artery-disease as a
`result of intensive lipid-lowering therapy in men with high levels of
`apolipoprotein B. N. Engl. J. Med. 323:1289-1298.
`Bryhn, M., et al., “The bioavailability and pharmacodynamics of
`different concentrations of omega-3 acid ethyl esters.”
`Prostaglandins, Leukotrienes and Essential Fatty Acids 75:19-24
`(2006).
`Budavari, S., Editor, The Merck Index, 1989, Merck & Co., Inc.,
`Rahway, N.J., entry 2417 on p. 379 and 451 1 on p. 725.
`Bunting, et al., “Depression in Parkinson's Disease'. J. Neurosci
`Nurs. Jun. 1991; 23(3): 158-164. (Abstract Only).
`Burdge, G.C., et al., “Eicosapentaenoic and docosapentaenoic acids
`are the principal products of a-linolenic acid metabolism in young
`men.” British Journal of Nutrition 88:355-363 (2002).
`Burdge, G.C., et al., “Lack of effect of meal fatty acid composition on
`postprandial lipid, glucose and insulin responses in men and women
`aged 50-65 years consuming their habitual diets.” British Journal of
`Nutrition, 96:489-500 (2006).
`Burdge, G.C., et al., “The effect of altering the 20:5n-3 and 22:6n-3
`content of a meal on the postprandial incorporation of n-3 polyun
`Saturated fatty acids into plasma triacylglycerol and non-esterified
`fatty acids in humans.” Prostaglandins, Leukotrienes and Essential
`Fatty Acids 77:59-65 (2007).
`Burr, M. L., et al., “Effects of changes in fat, fish and fibre intakes on
`death and myocardial reinfarction: Diet and reinfarction trial.” The
`Lancet, Sep. 30, 1989; 2(8666):757-61.
`Calabresi, L., et al., “Omacor in familial combined hyperlipidemia:
`effects on lipids and low density lipoprotein subclasses.” Atheroscle
`rosis 148:387-396 (2000).
`Campos, H., et al., "Lowdensity lipoprotein size, pravastatin treat
`ment, and coronary events.” JAMA. 2001:286: 1468-1474.
`Canner, P.L., et al., (1986) Fifteen year mortality in Coronary Drug
`Project patients: long-term benefit with niacin, J. Am. Coll. Cardiol.
`8. 1245-1255.
`
`Cao, J., et al., “Incorporation and Clearance of Omega-3 Fatty Acids
`in Erythrocyte Membranes and Plasma Phospholipids.” Clinical
`Chemistry 52(12):2265-2272 (2006).
`Cao, Y, et al., Genomics, vol. 49, "Cloning, Expression, and Chro
`mosomal Localization of Human Long-Chain Fatty Acid CoA Ligase
`4 (FACL4), pp. 327-330, 1998.
`Capuzzi, et al. “Efficacy and Safety of an Extended-Release Niacin
`(Niaspan): A Long-Term in Study.” Am J Cardiol 1998;82:74U-81U.
`Carlson, L.A. & Rosenhamer G. (1988). Reduction of mortaility in
`the Stockholm Ischaemic Heart Disease Secondary Prevention Study
`by combined treatment with clofibrate and nicotinic acid. Acta Med.
`Scand. 223,405-418.
`Carlson, L.A., Nicotinic acid: the broad-spectrum lipid drug. A 50"
`anniversary review, Journal of Internal Medicine, 2005:258:94-114.
`Carrero et al., “Intake of Fish Oil, Oleic Acid, Folic Acid, and Vita
`mins B-6 and E for 1 Year Decreases Plasma C-Reactive Protein and
`Reduces Coronary Heart Disease Risk Factors in Male Patients in a
`Cardiac Rehabilitation Program', pp. 384-390, 2007.
`Carroll, D. N., et al., “Evidence for the Cardioprotective Effects of
`Omega-3 Fatty Acids.” Ann Pharmacother. 36:1950-6 (2002).
`CaZZola, R., et al., "Age- and dose-dependent effects of an
`eicosapentaenoic acid-rich oil on cardiovascular risk factors in
`healthy male subjects.” Atherosclerosis 193: 159-167 (2007).
`Cefali, E.A. et al., “Aspirin reduces cutaneous flushing after admin
`istration of an optimized extended-release niacinformulation.” Inter
`national Journal of Clinical Pharmacology and Therapeutics, vol.
`45. No. 2/2007 (78-88).
`Centerfor Drug Evaluation and Research. Omacor (Lovaza) Medical
`Reviews 2004 (last accessed May 29, 2008 at http://www.fda.gov/
`cder/foi/nda/2004/21-654 Omacor Medrpdf).
`Center for Drug Evaluation and Research. Application No. 21-853,
`21654.s016. (Omacor). Statistical Review and Evaluation: Clinical
`Studies, Omacor (omega-3 acid ethyl ester) Capsules, 4 grams/day;
`2007. Available at: http://www.accessdata.fda.gov/drugsatfda
`docs/nda/2007/021853.s000:%20021654.s016 StatR.pdf. Accessed
`Jan. 26, 2012.
`Center for Drug Evaluation and Research. Approval Package for:
`21-654 (Omacor, Lovaza). Statistical Review; 2004. Available at:
`http://www.accessdata.fda.gov/drugsatfla docs/nda/2004/21
`654. Omacor AdminCorres P1.pdf. Accessed Jan. 26, 2012.
`Chan et al., “Effect of Atorvastatin and Fish Oil on Plasma High
`Sensitivity C-Reactive Protein Concentrations in Individuals with
`Visceral Obesity”, Clin. Chem., vol. 48, pp. 877-883 (2002).
`Chan, D.C., et al., “Randomized controlled trial of the effect of n-3
`fatty acid Supplementation on the metabolism of apolipoprotein
`B-100 and chylomicron remnants in men with visceral obesity.” Am
`J. Clin Nutr 77:300-7 (2003).
`Chapman, M.J., et al., “Cholesteryl ester transfer protein: at the heart
`of the action of lipid-modulating therapy with statins, fibrates, niacin,
`and cholesteryl ester transfer protein inhibitors.” Eur Heart J.
`2010:31:149-164.
`Chemical Book, Eicosapentaenoic acid ethyl ester, copyright 2010,
`printed Jun. 16, 2011 from www.chemicalbook.com.
`Chen, H., et al., “Eicosapentanoic acid inhibits hypoxia
`reoxygenation-induced injury by attenuating upregulation of MMP-1
`in adult rat myocytes.” Cardiovascular Research 59:7-13 (2003).
`Chen, H., et al., “EPA and DHA attenuate ox-LDL-induced expres
`sion of adhesion molecules in human coronary artery endothelial
`cells via protein kinase B pathway.” Journal of Molecular and Cel
`lular Cardiology 35:769-775 (2003).
`Chen, I.S., et al., “In vitro clearance of chylomicron triglycerides
`containing (co-3) eicosapentaenoate.” Atherosclerosis, 65:193-198
`(1987).
`Childs, M.T. et al., “Divergent lipoprotein Responses to Fish Oils
`With Various Ratios of Eicosapentaenoic Acid and Docasahexaenoic
`Acid'. American Society for Clinical Nutrition, 52.632-9, 1990.
`Christensen, J. H., et al., “Effect of fish oil on heart rate variability in
`Survivors of myocardial infarction: a double blind randomised con
`trolled trial.” BMJ, 312:677-678 (1996).
`Christensen, M.S., et al., “Intestinal absorption and lymphatic trans
`port of eicosapentaenoic (EPA), docosahexaenoic (DHA), and
`decanoic acids: dependence on intramolecular triacylglycerol struc
`ture.” Am J Clin Nutr 61:56-61 (1995).
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1001, p. 4 of 29
`
`

`

`US 8,642,077 B2
`Page 5
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Cleland, L.G., et al., “A Biomarker of n-3 compliance in patients
`taking fish oil for rheumatoid arthritis.” Lipids 38:419-424 (2003).
`Clinical Trial NCT01047501, Effect of AMR101 (Ethyl
`Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With
`HighTg Levels (>200 and <500 mg/dL) (ANCHOR), ClinicalTrials.
`gov database online). U.S. National Institute of Health, Jan. 2010
`retrieved Apr. 27, 2011). Retrieved from the Internet: <http://
`clinicaltrials.gov/ct2/show/NCT01047501 >.
`Cohen, J.D., et al., "30-year trends in serum lipids among United
`States adults: results from the National Health and Nutrition Exami
`nation Surveys II, III, and 1999-2006.” Am J Cardiol. 2010:106:969
`975.
`Cole et al., “Challenges and opportunities in the encapsulation of
`liquid and semi-solid formulations into capsules for oral administra
`tion.” Advanced Drug Delivery Reviews, vol. 60, No. 6, Dec. 21.
`2007, pp. 747-756.
`Colhoun, H.M., et al., “Primary prevention of cardiovascular disease
`with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin
`Diabetes Study (CARDS): multicentre randomised placebo-con
`trolled trial.” Lancet 364: 685-9 (2004).
`Collins, N., et al., “Differences between Dietary Supplement and
`Prescription Drug Omega-3 Fatty Acid Formulations: A Legislative
`and Regulatory Perspective.” Journal of the American College of
`Nutrition, 27 (6):659-666 (2008).
`Conklin, S. M., et al., "Serum (O-3 fatty acids are associated with
`variation in mood, personality and behavior in hypercholesterolemic
`community volunteers.” Psychiatry Research 152: 1-10 (2007).
`Connor et al., “Seminars in thrombosis and hemostasis” (1988)
`14:271-284.
`Connor, W.E., "Importance of n-3 Fatty Acids in Health and Dis
`ease”, Am. J. Clin. Nutr., 71(1(S)): 171S-175S, 2000.
`Conquer, J.A., et al., “Effect of supplementation with different doses
`of DHA on the levels of circulating DHA as non-esterified fatty acid
`in subjects of Asian Indian background. J. Lipid Res.” 1998:39:286
`292.
`Conquer, J.A., et al., “Supplementation with an algae source of
`docosahexaenoic acid increases (n-3) fatty acid status and alters
`Selected risk factors for heart disease in vegetarian Subjects. J Nutr.
`1996; 126: 3032-3039.
`Contacos et al. Effect of pravastatin and omega-3 fatty acids on
`plasma lipids and lipoproteins in patients with combined
`hyperlipidemia, pp. 1755-1762, 1993.
`Criqui, M.. “Triglycerides and Coronary Heart Disease Revisited
`(Again).” Sep. 18, 2007, vol. 147 No. 6, pp. 425-427.
`Crowe, F. L., et al., "Serum phospholipid n-3 long-chain polyunsatu
`rated fatty acids and physical and mental health in a population-based
`Survey of New Zealand adolescents and adults.” Am J Clin Nutr
`86: 1278-85 (2007).
`Daggy, B., et al., Dietary fish oil decreases VLDL production rates.
`Biochimica et Biophysics Acta 920: 293-300 (1987).
`Das, U.N., Essential fatty acids as possible mediators of the actions of
`statins. Prostaglandins, Leukotrienes and Essential Fatty Acids
`65(1):37-40, (2001).
`Davidson MH. Stein EA, Bays HE et al. “Efficacy and tolerability of
`adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d
`in hypertriglyceridemic patients: an 8-week, randomized, double
`blind, placebo-controlled study.” Clin Ther 2007:29:1354-1367.
`Davidson MH. (2006). “Mechanisms for the hypotriglyceridemic
`effect of marine omega-3 fatty acids.” Am J Cardiol 98(4A):27i-33i.
`Davidson, M.H., et al., “Effects of docosahexaenoic acid on serum
`lipoproteins in patients with combined hyperlipidemia: a random
`ized, doubleblind, placebo-controlled trial.” J Am Coll Nutr.
`1997:16:236-243.
`De Caterina, R. et al., “Control of Endothelial Leukocyte Adhesion
`Molecules by Fatty Acids.” Lipids, vol. 31:S57-S63 (1996).
`De Caterina, R., et al., “The Omega-3 fatty acid docosahexaenoate
`reduces cytokine-induced expression of proatherogenic and
`proinflammatory proteins in human endothelial cells.” Arterioscler.
`Thromb. Vasc. Biol. 14:1829-1836 (1994).
`
`Deckelbaum R. J., et al., "Conclusions and recommendations from
`the symposium, Beyond Cholesterol: Prevention and Treatment of
`Coronary Heart Disease with n-3 Fatty Acids.” Am J Clin Nutr
`87:2010S-12S (2008).
`Dewailly, E., et al., “n-3 Fatty acids and cardiovascular disease risk
`factors among the Inuit of Nunavik.” Am J Clin Nutr 74:464-73
`(2001).
`Diagnostic and Statistical Manual of Mental Disorders, 4. Sup.th. Ed,
`published by the American Psychiatric Assoc., pp. 285-286, 1994.
`Diagnostic and Statistical Manual of Mental Disorders, 4. Sup.th.
`Ed.text revision, published by the American Psychiatric Assoc., pp.
`154-163, and 369-381, 2000.
`Dijan, P. et al., Proc. Natl. Acad. Sci., vol. 93, "Codon repeats in
`genes associated ... ', pp. 417-421, Jan. 1996.
`Dijk, J. M., et al., “Carotid intima media thickness and the risk of
`new vascular events in patients with manifestatherosclerotic disease:
`the SMART study.” European Heart Journal 27:1971-1978 (2006).
`Dodin, S., et al., “Flaxseed on cardiovascular disease markers in
`healthy menopausal women: a randomized, double-blind, placebo
`controlled trial.” Nutrition 24:23-30 (2008).
`Dolecek, D.A., “Epidemiological Evidence of Relationships
`Between Dietary Polysunsaturated Fatty Acids and Morality in the
`Multiple Risk Factor Intervention Trial'. Society of Experimental
`Biology and Medicine, 200(2):177-182, 1991.
`Dullenmeijer, C., et al., “n-3 Fatty acid proportions in plasma and
`cognitive performance in older adults.” Am J Clin Nutr 86:1479-85
`(2007).
`Duncan, R. E., et al., “Regulation of HMG-CoA reductase in MCF-7
`cells by genistein, EPA, and DHA, alone and in combination with
`mevastatin.” Cancer Letters 224:221-228 (2005).
`Durrington PN et al. An omega-3 polyunsaturated fatty acid con
`centrate administered for one year decreased triglycerides in
`simvastatin treated patients with coronary heart disease and persis
`tent Hypertriglyceridemia.” Heart 2001: 85:544-48.
`Dwyer, J. H., et al., “Arachidonate 5-Lipoxygenase Promoter Geno
`type, Dietary Arachidonic Acid, and Atherosclerosis.' N. Engl. J.
`Med., 350:1 (2004).
`Dyerberg, J., et al., “Marine Oils and Thrombogenesis.” Prog. Lipid
`Res. 21:255-269 (1982).
`Egert, S., et al., “Dietary alpha-linolenic acid, EPA, and DHA have
`differential effects on LDL fatty acid composition but similar effects
`on serum lipid profiles in normolipidemic humans. J Nutr.
`2009; 139:861-868.
`Eisenberg S. Bilheimer DW. Levy RI, Lindgren FT. “On the meta
`bolic conversion of human plasma very low density lipoprotein to low
`density lipoprotein.” Biochim Biophys Acta 1973: 326:361-77.
`Eisenberg S. Rachmilewitz D. "Metabolism of rat plasma very low
`density lipoprotein. I. Fate in circulation of the whole lipoprotein.”
`Biochim Biophys Acta 1973: 326:378-90.
`Elam et al., Effect of Niacin on Lipid and Pipoprotein Levels and
`Glycemic Control in Patients With Diabetes and Peripheral Arterial
`Disease: The ADMIT Study: A Randomized Trial, JAMA,
`2000:284(10); 1263-1270.
`El-Sohemy, A., et. al., “Regulation of Mevalonate Synthesis in Low
`Density Lipoprotein Receptor Knockout Mice Fed n-3 or n-6 Poly
`unsaturated Fatty Acids.” Lipids, 34 (10): 1037-43 (1999).
`Engler, et al., “Docosahexaenoic acid restores endothelial function in
`children with hyperlipidemia: results from the EARLY Study.” Inter
`national Journal of Clinical Pharmacology and Therapeutics, vol.
`42 No. 12/2004 (672-679).
`Engler, M.B., et al., “Mechanisms of vasorelaxation induced by
`eicosapentaenoic acid (20:5n-3) in WKY rat aorta.” British Journal of
`Pharmacology 131: 1793-1799 (2000).
`Engler, M.M., et al., “The effects of a diet rich in docosahexaenoic
`acid on organ and vascular fatty acid composition in spontaneously
`hypertensive rats.” Prostaglandins, Leukotrienes and Essential Fatty
`Acids 61(5):289-295 (1999).
`Epadel R. Complete prescribing information). Update (Version 5).
`Tokyo, Japan: Mochida Pharmaceutical; Jan. 2007. (English transla
`tion).
`Faggin, E., et al., “Fish Oil Supplementation Prevents Neointima
`Formation in Nonhypercholesterolemic Balloon-Injured Rabbit
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1001, p. 5 of 29
`
`

`

`US 8,642,077 B2
`Page 6
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Carotid Artery by Reducing Medial and Advent